Načítá se...
Development of a peptide-drug conjugate for prostate cancer therapy
TGX-221 is a highly potent phosphoinositide 3-kinases β (PI3Kβ) inhibitor that holds great promise as a novel chemotherapeutic agent to treat prostate cancer. However, poor solubility and lack of targetability limit its therapeutic applications. The objective of this present study is to develop a pe...
Uloženo v:
| Hlavní autoři: | , , , , |
|---|---|
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
2011
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3163154/ https://ncbi.nlm.nih.gov/pubmed/21510670 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1021/mp200007b |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|